

Arkansas Blue Cross and Blue Shield FEP Drug List

The purpose of this document is to provide the location of the medical necessity criteria that Magellan Rx Management will require to render clinical determinations for the Medical Pharmacy Prior Approval program. Additional information can be obtained by visiting the FEP website. **Please note that both websites also contain links to policies that are not managed in the prior approval program administered by Magellan Rx Management on behalf of Arkansas Blue Cross and Blue Shield FEP.**

HCPSCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J3262	Actemra IV	tocilizumab	BDAID: Rheumatoid Arthritis	3/1/2022	5.70.12	CVS
J0800	Acthar HP	corticotropin	Corticotropin, Acth	3/1/2022	40328	CVS
J0791	Adakveo	crizanlizumab-tmca	Rare Disease	3/1/2022	5.85.36	CVS
J9042	Adcetris	brentuximab vedotin	Oncology	3/1/2022	43606	CVS
J1454	Akynzeo IV	fosnetupitant/palonosetron	Antiemetics	3/1/2022	5.50.05	CVS
J2469	Aloxi	palonosetron	Antiemetics	3/1/2022	5.50.15	CVS
Q5126	Alymsys	bevacizumab-maly	Oncology	1/1/2024	5.21.004	CVS
J0225	Amvuttra	vutrisiran		1/1/2024	5.75.037	CVS
J0256	Aralast NP	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	CVS
J0881	Aranesp (non-ESRD)	darbepoetin	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.01	CVS
J9302	Arzerra	ofatumumab	Oncology	3/1/2022	37762	CVS
J1554	Asceniv	immune globulin intravenous, human – slra	Immune Globulin	3/1/2022	37761	CVS
J9035	Avastin (oncology only)	bevacizumab	Oncology	3/1/2022	5.21.004	CVS
Q5121	Avsola	infliximab-axxq	BDAID	3/1/2022	5.50.002	CVS
J9023	Bavencio	avelumab	Oncology	3/1/2022	32649	CVS
J9032	Beleodaq	belinostat	Oncology	3/1/2022	54199	CVS
J9036	Belrapzo	bendamustine	Oncology	3/1/2022	52372	CVS
J9058	Bendamustine - Apotex	bendamustine (Apotex)	Oncology	7/1/2023	5.21.043	CVS
J9059	Bendamustine - Baxter	bendamustine (Baxter)	Oncology	7/1/2023	5.21.043	CVS
J9034	Bendeka	bendamustine	Oncology	3/1/2022	5.21.043	CVS
J0490	Benlysta IV	belimumab	BDAID: Systemic Lupus Erythematosus	3/1/2022	5.99.01	CVS
J0179	Beovu	brolicizumab-dbll	Ophthalmic Injections	3/1/2022	5.90.026	CVS
J0597	Berinert	c1 esterase inhibitor (human)	Hereditary Angioedema	3/1/2022	5.85.02	CVS
J9229	Besponsa	inotuzumab ozogamicin	Oncology	3/1/2022	5.21.100	CVS
J1556	Bivigam	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J9039	Blincyto	blinatumomab	Oncology	3/1/2022	18769	CVS
J9046	Bortezomib	bortezomib	Oncology	3/1/2022	5.21.045	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J9048	Bortezomib	bortezomib	Oncology	3/1/2022	5.21.045	CVS
J9049	Bortezomib	bortezomib	Oncology	3/1/2022	5.21.045	CVS
J9051	Bortezomib	bortezomib (Maia)	Oncology	10/1/2023	5.21.045	CVS
J0585	Botox	onabotulinumtoxina	Botulinum Toxins	3/1/2022	5.75.01	CVS
Q5124	Byooviz	ranibizumab-nuna	Ophthalmic Injections	1/1/2024	5.90.029	CVS
J1786	Cerezyme	imiglucerase	Enzyme Replacement Therapy	3/1/2022	5.85.04	CVS
Q5128	Cimerli	ranibizumab-eqrn	Ophthalmic Injections	1/1/2024	5.90.029	CVS
J0717	Cimzia	certolizumab pegol	BDAID	3/1/2022	5.50.11	CVS
J2786	Cinqair	reslizumab	Asthma/COPD	3/1/2022	5.45.08	CVS
J0598	Cinryze	c-1 esterase inhibitor human	Hereditary Angioedema	3/1/2022	5.85.05	CVS
J0584	Crysvita	burosumab-twza	Enzyme Replacement Therapy	3/1/2022	19144	CVS
90284/ J3590	Cutaquig	immune globulin subcutaneous (human) - hipp	Immune Globulin	3/1/2022	39588	CVS
J1555	Cuvitru	subcutaneous immune globulin	Immune Globulin	3/1/2022	39588	CVS
J9308	Cyramza	ramucirumab	Oncology	3/1/2022	52738	CVS
J9145	Darzalex	daratumumab	Oncology	3/1/2022	25709	CVS
J9144	Darzalex Faspro	daratumumab; hyaluronidase-fihj	Oncology	3/1/2022	5.21.147	CVS
J7318	Durolane	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J0586	Dysport	abobotulinumtoxina	Botulinum Toxins	3/1/2022	5.75.02	CVS
J3060	Elleyso	taliglucerase alfa	Enzyme Replacement Therapy	3/1/2022	5.85.14	CVS
J9176	Empliciti	elotuzumab	Oncology	3/1/2022	26805	CVS
J9358	Enhertu	fam-trastuzumab deruxtecan-nxki	Oncology	3/1/2022	5.21.138	CVS
J3380	Entyvio	vedolizumab	BDAID: Crohns Disease/Ulcerative Colitis	3/1/2022	5.50.12	CVS
J1325	Epoprostenol	epoprostenol	Pulmonary Arterial Hypertension	3/1/2022	5.40.15	CVS
J9055	Erbitux	cetuximab	Oncology	3/1/2022	30823	CVS
J7323	Euflexxa	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09	CVS
J3111	Evenity	romosozumab-aqqg	Osteoporosis	3/1/2022	23161	CVS
J1428	Exondys 51	eteplirsen	CNS Agents: Rare Diseases	3/1/2022	5.75.14	CVS
J0178	Eylea	aflibercept	Ophthalmic Injections	3/1/2022	5.90.026	CVS
J0517	Fasenra	benralizumab	Asthma/COPD	3/1/2022	5.45.07	CVS
J9155	Firmagon	degarelix	Oncology	3/1/2022	50920	CVS
J1572	Flebogamma	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J1325	Flolan	"epoprostenol (flolan/veltri)"	Pulmonary Arterial Hypertension	3/1/2022	5.40.15	CVS
Q5108	Fulphila	pegfilgrastim-jmdb	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
Q5130	Fylnetra	pegfilgrastim-pbbk	Colony-Stimulating Factors	1/1/2024	5.85.009	CVS
J1569	Gammagard Liquid	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J1566	Gammagard S/D (powder)	immune globulin	Immune Globulin	3/1/2022	37761	CVS
J1561	Gammaked	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J1557	Gammaplex	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J1561	Gamunex-C	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J9301	Gazyva	obinutuzumab	Oncology	3/1/2022	47259	CVS
J7326	Gel-One	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7328	Gel-Syn	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7320	GenVisc 850	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J0223	Givlaari	givosiran	Rare Disease	1/1/2023	5.85.037	CVS
J0257	Glassia	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	CVS
J1447	Granix	tbo-filgrastim	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
J0599	Haegarda	c1-esterase inhibitor	Hereditary Angioedema	3/1/2022	5.85.26	CVS
J9179	Halaven	eribulin	Oncology	3/1/2022	27901	CVS
J9355	Herceptin	trastuzumab	Oncology	3/1/2022	5.21.2006	CVS
J9356	Herceptin Hylecta	hyaluronidase-oysk/trastuzumab	Oncology	3/1/2022	5.21.126	CVS
Q5113	Herzuma	trastuzumab-pkrb	Oncology	3/1/2022	5.21.2006	CVS
J1559	Hizentra	injection, immune globulin	Immune Globulin	3/1/2022	39588	CVS
J7321	Hyalgan	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7322	Hymovis	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J1575	HyQvia	injection, immune globulin/ hyaluronidase	Immune Globulin	3/1/2022	39588	CVS
J3245	Ilumya	tildrakizumab	BDAID: Psoriasis/Psoriatic Arthritis	3/1/2022	5.90.35	CVS
J9173	Imfinzi	durvalumab	Oncology	3/1/2022	34475	CVS
Q5103	Inflectra	infliximab-dyyb	Autoimmune	3/1/2022	5.50.002	CVS
J9043	Jevtana	cabazitaxel	Oncology	3/1/2022	46528	CVS
J9064	Jevtana	Cabazitaxel (sandoz)	Oncology	10/1/2023	5.21.027	CVS
J9354	Kadcyla	ado-trastuzumab emtansine	Oncology	3/1/2022	48355	CVS
J1290	Kalbitor	ecallantide	Hereditary Angioedema	3/1/2022	5.85.07	CVS
Q5117	Kanjinti	trastuzumab-anns	Oncology	3/1/2022	5.21.2006	CVS
J9271	Keytruda	pembrolizumab	Oncology	3/1/2022	18404	CVS
J2507	Krystexxa	pegloticase	Gout	3/1/2022	5.70.14	CVS
J9047	Kyprolis	carfilzomib	Oncology	3/1/2022	45433	CVS
J0202	Lemtrada	alemtuzumab	Multiple Sclerosis	3/1/2022	5.60.23	CVS
J2820	Leukine	sargramostim	Colony-Stimulating Factors	3/1/2022	5.85.08	CVS
J9119	Libtayo	cemiplimab-rwlc	Oncology	3/1/2022	5.21.118	FEP
J2778	Lucentis	ranizumab	Ophthalmic Injections	3/1/2022	5.90.029	CVS

HCPDS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J3398	Luxturna	voretigene	Ophthalmic Injections	3/1/2022	5.90.33	FEP
J0888	Mircera (non ESRD)	epoetin beta	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.21	CVS
J7327	Monovisc	hyaluronic acid	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
Q5107	Mvasi	bevacizumab-awwb	Oncology	3/1/2022	38128	CVS
J0587	Myobloc	rimabotulinumtoxinb	Botulinum Toxins	3/1/2022	5.75.03	CVS
J2506	Neulasta	pegfilgrastim	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
J1442	Neupogen	filgrastim	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
Q5110	Nivestym	filgrastim-aafi	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
J2796	Nplate	romiplostim	Hematology	3/1/2022	5.85.20	CVS
J2182	Nucala	meprolizumab	Asthma/COPD	3/1/2022	5.45.07	CVS
Q5122	Nyvepria	pegfilgrastim-apgf	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
J2350	Ocrevus	ocrelizumab	Multiple Sclerosis	3/1/2022	5.60.28	CVS
J1568	Octagam	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
Q5114	Ogivri	trastuzumab-dkst	Oncology	3/1/2022	5.21.2006	CVS
J9205	Onivyde	irinotecan liposome	Oncology	3/1/2022	24613	CVS
J0222	Onpattro	patisiran	Rare Disease	3/1/2022	5.75.23	FEP
Q5112	Ontruzant	trastuzumab-dttb	Oncology	3/1/2022	5.21.2006	CVS
J9299	Opdivo	nivolumab	Oncology	3/1/2022	19500	CVS
J0129	Orencia IV	abatacept	BDAID: Rheumatoid Arthritis	3/1/2022	5.70.18	CVS
J7324	Orthovisc	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J0224	Oxlumo	lumasiran	Rare Disease	1/1/2023	5.55.002	CVS
J9177	Padcev	enfortumab vedotin-ejfv	Oncology	3/1/2022	5.21.137	CVS
J1599	Panzyga	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J9306	Perjeta	pertuzumab	Oncology	3/1/2022	43972	CVS
J9309	Polivy	polatuzumab vedotin-piiq	Oncology	3/1/2022	5.21.129	CVS
J9295	Portrazza	necitumumab	Oncology	3/1/2022	26440	CVS
J9204	Poteligeo	mogamulizumab-kpkc	Oncology	3/1/2022	5.21.114	CVS
J1459	Privigen	intravenous immune globulin	Immune Globulin	3/1/2022	37761	CVS
J0885	Procrit/Epogen (non ESRD)	epoetin alfa	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.06	CVS
J0256	Prolastin-C	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	FEP
J0897	Prolia	denosumab	Oncology	3/1/2022	42885	CVS
Q2043	Provenge	sipuleucel-t	Oncology	3/1/2022	39954	CVS
J1301	Radicava	edaravone	Enzyme Replacement Therapy	3/1/2022	5.75.20	CVS
Q5125	Releuko	filgrastim-ayow	Colony-Stimulating Factors	1/1/2024	5.85.010	CVS
J1745	Remicade	infliximab	Autoimmune	3/1/2022	5.50.002	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J3285	Remodulin	treprostinil	Pulmonary Arterial Hypertension	3/1/2022	5.40.17	CVS
Q5104	Renflexis	infliximab-abda	Autoimmune	3/1/2022	5.50.002	CVS
Q5106	Retacrit	epoetin alfa-epbx	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.06	CVS
J3490	Revatio	sildenafil	Pulmonary Arterial Hypertension	3/1/2022	5.40.11	CVS
Q5123	Riabni	rituximab-arrx	Oncology	1/1/2024	5.21.010	CVS
J9312	Rituxan	rituximab	Oncology	3/1/2022	5.21.2010	CVS
J9311	Rituxan Hycela	rituxumab hyaluronidase	Oncology	3/1/2022	5.21.096	CVS
J1449	Rolvedon	eflapegrastim-xnst		1/1/2024	5.85.047	CVS
J0596	Ruconest	c1 esterase inhibitor (recombinant)	Hereditary Angioedema	3/1/2022	5.85.17	CVS
Q5119	Ruxience	rituximab-pvvr	Oncology	3/1/2022	5.21.2010	CVS
J2353	Sandostatin LAR Depot	octreotide lar	Gastrointestinal: Chemoprotectant/ Hormonal	3/1/2022	39963	CVS
J2502	Signifor LAR	pasireotide	Hormones	3/1/2022	46172	CVS
J1602	Simponi Aria	golimumab	BDAID	3/1/2022	5.70.51	CVS
J2327	Skyrizi IV	risankizumab-rzaa		10/1/2023	5.90.038	CVS
J7331	Sodium Hyaluronate	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J1300	Soliris	eculizumab	Hematology	3/1/2022	5.85.11	CVS
J1930	Somatuline depot	lanreotide	Endocrine Disorders	3/1/2022	46537	CVS
J2326	Spinraza	nusinersen	CNS Agents: Rare Diseases	3/1/2022	5.75.15	FEP
J3358	Stelara IV	ustekinumab	BDAID: Crohns Disease/Ulcerative Colitis	3/1/2022	5.90.04	CVS
J3490	Strensiq	asfotase alfa	Rare Disease	3/1/2022	42154	CVS
J7321	Supartz FX	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J1627	Sustol	granisetron extended-release	Antiemetics	3/1/2022	5.50.15	CVS
90378	Synagis	palivizumab	Immunizing Agent	3/1/2022	38127	CVS
J7331	Synojoint	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7325	Synvisc	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7325	Synvisc One	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J9022	Tecentriq	atezolizumab	Oncology	3/1/2022	29362	CVS
J3490	Tegsedi	inotersen	TRR Amyloidosis	1/1/2023	5.75.025	CVS
J3241	Tepezza	teprotumumab-trbw	Rare Disease	3/1/2022	23527	CVS
S0189	Testopel	testosterone pellets	Endocrine Disorders	3/1/2022	48729	CVS
Q5116	Trazimera	trastuzumab-qyyp	Oncology	3/1/2022	5.21.2006	CVS
J9033	Treanda	bendamustine	Oncology	3/1/2022	52372	CVS
J7332	Triluron	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS

HCPDS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J9317	Trodelyv	sacituzumab govitecan-hziy	Oncology	3/1/2022	5.21.145	CVS
Q5115	Truxima	rituxumab-abbs	Oncology	3/1/2022	5.21.2010	CVS
J2323	Tysabri	natalizumab	Multiple Sclerosis	3/1/2022	5.60.13	CVS
Q5111	Udenyca	pegfilgrastim-cbqv	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
J1303	Ultomiris	ravulizumab-cwvz	Rare Disease	3/1/2022	5.85.33	CVS
J1823	Uplizna	inebilizumab-cdon	Rare Disease	3/1/2022	5.99.18	FEP
J2777	Vabysmo	faricimab-svoa	Ophthalmic Injections	1/1/2024	5.90.026	CVS
J9303	Vectibix	panitumumab	Oncology	3/1/2022	31188	CVS
Q5129	Vegzelma	bevacizumab-adcd	Oncology	1/1/2024	5.21.004	CVS
J9041	Velcade	bortezomib	Oncology	3/1/2022	53103	CVS
J1325	Veletri	epoprostenol	Pulmonary Arterial Hypertension	3/1/2022	5.40.15	CVS
J7321	Visco-3	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J3385	Vpriv	velaglucerase alfa	Enzyme Replacement Therapy	3/1/2022	5.85.12	CVS
J3032	Vyepti	eptinezumab-jjmr	CNS Agents: Migraine	3/1/2022	5.70.81	CVS
J1429	Vyondys-53	golodirsen	CNS Agents: Rare Diseases	3/1/2022	5.75.31	CVS
J9332	Vyvgart	efgartigimod alfa-fcab	Neurologic Disorders	1/1/2023	5.99.026	FEP
J3590	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	Neurologic Disorders	1/1/2024	5.99.026	FEP
J1558	Xembify	immune globulin human - klhw	Immune Globulin	3/1/2022	43972	CVS
J0588	Xeomin	incobotulinumtoxina	Botulinum Toxins	3/1/2022	5.75.04	CVS
J0897	Xgeva	denosumab	Oncology	3/1/2022	42885	CVS
J2357	Xolair	omalizumab	Asthma/COPD	3/1/2022	5.45.02	CVS
J9228	Yervoy	ipilimumab	Oncology	3/1/2022	41415	CVS
J9352	Yondelis	trabectedin	Oncology	3/1/2022	23883	CVS
J9400	Zaltrap	ziv-aflibercept	Oncology	3/1/2022	45798	CVS
Q5101	Zarxio	filgrastim-sndz	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
J0256	Zemaira	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	CVS
J9223	Zepzelca	lurbinectedin	Oncology	3/1/2022	5.21.152	CVS
Q5120	Ziextenzo	pegfilgrastim-bmez	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
Q5118	Zirabev	bevacizumab-bvzr	Oncology	3/1/2022	38128	CVS
J9202	Zoladex	goserelin acetate implant	Oncology	3/1/2022	50920	CVS
J3399	Zolgensma	onasemnogene abeparvovec	Rare Disease	3/1/2022	5.75.27	FEP

Other drugs may require prior approval through Arkansas Blue Cross and Blue Shield, and the above list subject to change.

To view additional resources, please visit arkansasbluecross.com/providers/resource-center/specialty-pharmacy.

00342.03.01-0124